Evaluation of levofloxacin dosage regimens to prevent the appearance of resistant mutants in Streptococcus pneumoniae and Escherichia coli using an in vitro simulation model

Japanese Journal of Chemotherapy

Volumn 57, Issue 1, 2009, Pages 1-4

  Kanda, Hiroko ^a   Chiba, Megumi ^a   Inoue, Kazue ^a   Hoshino, Kazuki ^a   Tanaka, Mayumi ^a   Otani, Tsuyoshi ^a   Hori, Seiji ^b   Totsuka, Kyoichi ^c  

^a DAIICHI SANKYO CO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Escherichia coli; In vitro; Levofloxacin; Simulation; Streptococcus pneumoniae

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

EID: 59649090048     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Yamaguchi K, Ohno A, the Levofloxacin Surveillance Group: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn Microbiol Infect Dis 2005; 52: 135-43
2. Japanese source.
3. Japanese source.
4. Japanese source.
5. Japanese source.
6. Lacy M K, Lu W, Xu X, Tessier P R, Nicolau D P, Quintiliani R, et al: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43: 672-7
7. Andes D, Craig W A: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-8
8. Craig W A: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
9. Craig W A: Does dose matter? Clin Infect Dis 2001; 33 Suppl 3: S233-7
10. Madaras-Kelly K J, Demasters T A: In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetic of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 37: 253-60
11. Preston S L, Drusano G L, Berman A L, Fowler C L, Chow A T, Dornseif B, et al: Pharmacodynamics of levofloxacin. J Am Med Assoc 1998; 279: 125-9
12. Blaser J, Stone B B, Groner M C, Zinner S H: Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60
13. Schubert S, Dalhoff A, Stass H, Ullmann U: Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Infection 2005; 33 Suppl 2: 15-21
14. Zhanel G G, Walters M, Laing N, Hoban D J: In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 435-40
15. Lister P D, Sanders C C: Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrobiol Chemother 1999; 43: 79-86
16. Coyle E A, Kaatz G W, Rybak M J: Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 1654-9
17. Frimodt-Møller N: Correlation between pharmacokinetic/ pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 19: 546-53
18. Wagenlehner F M, Weidner W, Naber K G: Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. J Hosp Infect 2005; 60: 191-200
19. Madaras-Kelly K J, Ostergaard B E, Hovde L B, Rotschafer J C: Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-32
20. Dudley M N, Blaser J, Gilbert D, Mayer K H, Zinner S H: Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis 1991; 164: 499-506
21. Carson C, Naber K G: Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs 2004; 64: 1359-73
22. Fukuda Y, Takahata M, Mitsuyama J: Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration. J Infect Chemother 2006; 12: 1-8
23. Piddock L J, Johnson M M, Simjee S, Pumbwe L: Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 808-12
24. Louie A, Brown D L, Liu W, Kulawy R W, Deziel M R, Drusano G L: In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 3988-4000
25. Jumbe N L, Louie A, Miller M H, Liu W, Deziel M R, Tam V H, et al: Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 310-7
26. Heisig P, Tschorny R: Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91
27. Cohen S P, Hooper D C, Wolfson J S, Souza K S, McMurry L M, Levy S B: Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1998; 32: 1187-91
28. Chenia H Y, Pillay B, Pillay D: Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006; 58: 1274-8
29. Canton R, Morosini M, Enright M C, Morrissey I: Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT. surveillance programme. J Antimicrob Chemother 2003; 52: 944-52
30. Lim S, Bast D, McGeer A, de Azavedo J, Low D E: Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9: 833-7
31. Davies T A, Evangelista A, Pfleger S, Bush K, Sahm D F, Goldschmidt R: Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002; 46: 119-24
32. Jones M E, Sahm D F, Martin N, Scheuring S, Heisig P, Thornsberry C, et al: Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumonaie with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462-6
33. Weigel L M, Anderson G J, Facklam R R, Tenover F C: Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 3517-23
34. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T: Dual-targeting properties of 3-aminopyrrolidyl quinolones, DC-159 a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution in reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008; 62: 98-104
35. Zhanel G G, Walkty A, Nichol K, Smith H, Noreddin A, Hoban D J: Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003; 45: 63-7
36. Homma T, Hori T, Sugimori G, Yamano Y: Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 11: 3810-5
37. Schafer J, Hovde L B, Simonson D, Rotschafer J C: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis 2008; 60: 155-61
38. Garrison M W, Schimmels J A, Madaras-Kelly K J: In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn Microbiol Infect Dis 2003; 47: 587-93